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Fulgencio.Gomez@chuv.chSummaryMedical therapy for Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia (BMAH) is generally
administered for a limited time before surgery. Aberrant receptors antagonists show inconsistent efficacy in the long
run to prevent adrenalectomy. We present a patient with BMAH, treated for 10 years with low doses of ketoconazole
to control cortisol secretion. A 48-year-old woman presented with headaches and hypertension. Investigations showed
the following: no clinical signs of Cushing’s syndrome; enlarged lobulated adrenals; normal creatinine, potassium,
and aldosterone; normal urinary aldosterone and metanephrines; elevated urinary free cortisol and steroid metabolites;
and suppressed plasma renin activity and ACTH. A screening protocol for aberrant adrenal receptors failed to show any
illegitimate hormone dependence. Ketoconazole caused rapid normalisation of cortisol and ACTH that persists over 10 years
on treatment, while adrenals show no change in shape or size. Ketoconazole decreases cortisol in patients with Cushing’s
syndrome, and may prevent adrenal overgrowth. Steroid secretion in BMAH is inefficient as compared with normal adrenals
or secreting tumours and can be controlled with low, well-tolerated doses of ketoconazole, as an alternative to surgery.Learning points:
† Enlarged, macronodular adrenals are often incidentally found during the investigation of hypertension in patients
harboring BMAH. Although laboratory findings include low ACTH and elevated cortisol, the majority of patients do
not display cushingoid features.
† Bilateral adrenalectomy, followed by life-long steroid replacement, is the usual treatment of this benign condition,
and alternative medical therapy is sought. Therapy based on aberrant adrenal receptors gives disappointing results,
and inhibitors of steroidogenesis are not always well tolerated.
† However, ketoconazole at low, well-tolerated doses appeared appropriate to control adrenal steroid secretion
indefinitely, while preventing adrenal overgrowth. This treatment probably constitutes the most convenient
long-term alternative to surgery.Background
Hypercorticism with low plasma adrenocorticotrophin
(ACTH) and cell proliferation in patients with macro-
nodular adrenal hyperplasia is ascribed to intrinsic
adrenal changes, that include the frequent expression of
aberrant G-protein-coupled receptors in the membranes ofsteroidogenic cells that are stimulated by a variety of
circulating ligands (1) (2), and a possible paracrine effect of
corticotropin produced by the same hyperplastic adrenal
tissue (3). In addition, germline and somatic inactivating
mutations of a putative tumour-suppressor gene, arma-
dillo repeat containing 5 (ARMC5), were recently found inhttp://www.edmcasereports.com
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Figure 1
Abdominal CT-scan at baseline (A) and after 10 years on low-dose
ketoconazole (B). Multi-lobulated bilateral adrenal masses are observed,
which remain unchanged in morphology after 10 years of treatment.
Volume was calculated using the ellipsoid formula p abc/6 (ml): (a)
anterior–posterior, (b) transversal, and (c) cranial–caudal maximal diam-
eters. (A) Right adrenal 12.9 ml and left adrenal 20.5 ml. (B) Right adrenal
14.7 ml and left adrenal 20.9 ml. Hepatic cysts are due to familial polycystic
liver disease.
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macronodular adrenal hyperplasia (BMAH) (4), and an
autosomal dominant mode of inheritance was further
characterised (5). Therefore, the terms ‘primary’ or merely
‘bilateral’ macronodular adrenal hyperplasia (and thus the
acronyms PMAH or BMAH) could be most appropriate
to qualify the syndrome of macronodular adrenal hyper-
plasia with hypercorticism, which was formerly termed
‘ACTH-independent’ (3) (6).
At the present time, there are no guidelines for the
management of this rare condition and, notwithstanding
its benign nature, most patients receiving medical therapy
for BMAH finally resolve to undergo surgical adrenalect-
omy (7). Medical therapy based on aberrant adrenal
receptors give inconsistent results for the long-term
control of steroid secretion, either with receptor antagon-
ists (8) or with somatostatin analogues that suppress illicit
ligands (9) (10). On the other hand, prolonged treatment
with inhibitors of steroidogenesis can be hampered by
drug intolerance, yet a lifelong treatment would be
required to avoid surgery. In fact, reports on prolonged
inhibition of steroidogenesis in BMAH are scanty. Trilos-
tane, a 3b-hydroxysteroid dehydrogenase inhibitor, did
not prevent continuing adrenal growth during a 4-year
treatment period, despite partial suppression of cortisol
production per adrenal mass with clinical improvement
(11). Metyrapone, an 11b-hydroxylase inhibitor, has long
been used to treat severe forms of Cushing’s syndrome,
but may cause hypoadrenalism and hyperandrogenism as
the most common side-effects (12). However, it was
successfully used in two Japanese patients with BMAH,
including one woman treated for 7 years and presenting
no hirsutism (13) (14). Ketoconazole is an antifungal agent
that also reduces adrenal and gonadal steroid production
via the inhibition of several steroidogenic enzymes
(11b-hydroxylase, 17a-hydroxylase and 18-hydroxylase),
as well as cholesterol side-chain cleavage (15), and has
been widely used as a palliative treatment or as an
alternative to surgery in different forms of Cushing’s
syndrome, at doses as high as 1200 mg/day. As this drug
does not induce adrenal hyperandrogenism, it could be
an interesting option in women. Many cases of BMAH
are incidentally discovered, with little or no cushingoid
features despite markedly enlarged adrenals (1) (2),
suggesting relatively inefficient cortisol secretion by the
macronodular tissue, which might respond to lower doses
of ketoconazole for steroid control.
To our knowledge, only one case of successful
treatment with ketoconazole has been reported in
BMAH, during a 1-year therapy until adrenalectomy washttp://www.edmcasereports.comperformed, at doses that were not mentioned (10). We
present a patient with BMAH without any evidence
of illegitimate hormone dependence, treated successfully
during 10 years with well-tolerated low doses of
ketoconazole.Case presentation
A 48-year-old woman presented with sudden headaches
and new-onset marked hypertension. She had no signs of
Cushing’s syndrome. She was known for familial (mother
and brother) asymptomatic polycystic liver disease with-
out kidney involvement. Abdominal ultrasound study
showed normal kidneys, numerous hepatic cysts and
unexpected large multi-lobulated bilateral adrenal masses,
confirmed on CT-scan (Fig. 1A). Laboratory studies
showed normal serum creatinine and urinary metane-
phrines; low-normal serum potassium (3.85 mmol/l;
normal range 3.50–5.20 mmol/l), normal plasma aldo-
sterone concentration (62 ng/l; 29–76 ng/l), normal urine
aldosterone (4.1 mg/24 h; 1.0–10.0 mg/24 h) and suppre-
ssed plasma renin activity (!0.05 mg/l per h; 0.20–2.00);
elevated urine tetrahydro-metabolites of 11-deoxycortisol
(THS, 396 mg/24 h; 10–109 mg/24 h), corticosterone
(THB, 509 mg/24 h; 26–262 mg/24 h), cortisone (THE,
6877 mg/24 h; 727–3815 mg/24 h) and cortisol (THF,
3031 mg/24 h; 458–1907 mg/24 h); elevated urine free
cortisol (349 nmol/24 h; 55–248 nmol/24 h); normal
plasma AM cortisol (309 nmol/l; 200–700 nmol/l at
0800 h) and slightly elevated PM cortisol (365 nmol/l;
60–300 nmol/l, at 1700 h), low ACTH (5 ng/l; 10–60 ng/l)
and suppressed DHEAS (!0.5 mmol/l; 1.6–7.0 mmol/l).2
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Figure 2
Urinary free cortisol and plasma ACTH after starting ketoconazole. Normal
values of urinary free cortisol are shown with the shaded area.
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Repeat measurements showed undetectable ACTH and
DHEAS and elevated plasma cortisol. A cosyntropin
test (0.25 mg as i.v. bolus) elicited an intense plasma
cortisol response (from basal 444 nmol/l to 1147 nmol/l,
C158%, at 60 min) and urine free cortisol response
(2776 nmol/24 h on the test day and 2036 nmol/24 h
on the day after), indicating high adrenal sensitivity
to ACTH.
BMAH was diagnosed and a screening protocol for
aberrant adrenal receptors was performed according
to Lacroix et al. (16). No significant increase in plasma
cortisol (less thanC25% of basal value) was observed after
a mixed meal of 500 kcal, 40% carbohydrates, 35% lipids,
and 25% proteins (K18% of basal value), and orthostatism
(C11%), metoclopramide 20 mg p.o. (C8%), glucagon
1 mg i.v. bolus (C5%), gonadotrophin-releasing hormone
0.1 mg i.v. bolus (C19%), follicle-stimulating hormone
300 IU i.m. (C10%), human chorionic gonadotrophin
1000 IU i.m. (C4%), or thyrotrophin-releasing hormone
0.2 mg i.v. bolus (C2%), and no decrease was observed
after propranolol 80 mg p.o. (C28%). ACTH was unde-
tectable during these tests. It was concluded that there
were no aberrant receptors sensitive to the hormonal
systems explored.Treatment
After appropriate information and discussion with
the patient, medical therapy was preferred to bilateral
adrenalectomy and life-long steroid replacement.
Medical inhibition of adrenal steroidogenesis with oral
ketoconazole was initiated, at 200 mg/day and then
400 mg/day, with a rapid decrease in urine free cortisol
and increase in plasma ACTH to normal. Blood pressure
was rapidly normalised and eventually required only small
doses of spironolactone (25 mg/day) and metoprolol
(100 mg/day).Outcome and follow-up
Cortisol and ACTH have remained normal throughout
more than 10 years on treatment (Fig. 2); however, DHEAS
remained undetectable. Bone mineral density (BMD) at
diagnosis showed hip-cortical osteopenia and normal
lumbar spine trabecular density T-scores. Control BMD
at 7 years of treatment showed an unchanged cortical
value, corresponding to a relative increase in BMD with
a Z-score at percentile 30–40, and a normal trabecularhttp://www.edmcasereports.comdensity with an unchanged Z-score at percentile 50.
Ketoconazole is well tolerated, with no signs of drug
toxicity on repeat liver enzymes, creatinine levels and
electrocardiogram. Repeat CT-scan studies show no
significant changes in macronodular adrenals and liver
cysts (Fig. 1B). Adrenal glands were measured on CT scans
and volume was calculated using the ellipsoid formula p
abc/6 (ml): (a) anterior–posterior, (b) transversal, and (c)
cranial–caudal maximal diameters. Control at 10 years
showed a minimal increase of 1.8 ml in the right adrenal
and of 0.4 ml in the left gland.Discussion
Although the natural growth of adrenal masses in BMAH
has not been widely documented, studies in familial
BMAH have identified adrenal nodules in asymptomatic
young relatives with germline mutations in ARMC5 (4).
Careful measurements of adrenal volume on serial CT
scans performed in one patient showed a progressive
increase in the adrenal volume, which was not slowed
with chemical single-enzyme inhibition of steroidogenesis
despite adequate cortisol suppression (11). These obser-
vations confirm the generally admitted dissociation
between adrenal growth and cortisol secretion and suggest
slow mass progression before excess cortisol becomes
apparent. Enlarged macronodular adrenals are often3
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tension (1) (2), as in the patient described here. Hyperten-
sion in our patient was largely due to excess adrenocortical
secretion, as corroborated by the response to medical
inhibition of adrenal steroidogenesis. Precursor miner-
alocorticoids probably contributed to hypertension, as
suggested by elevated urinary metabolites and low
aldosterone and renin levels observed in our patient.
Predominant co-secretion of precursor mineralocorti-
coids, and low aldosterone and renin levels, were
previously reported in Japanese patients with BMAH,
who had slightly elevated cortisol levels (17) (18) (19).
The high sensitivity to corticotropin displayed by our
patient despite prolonged suppression of pituitary ACTH
is consistent with a paracrine priming effect on steroido-
genic cells, exerted by ACTH produced in situ within the
same macronodular adrenals (3). Suppressed DHEAS at
presentation may be ascribed to low circulating ACTH,
but persistent suppressed DHEAS despite normal ACTH
during treatment could be a direct effect of ketoconazole
(suppression of 17a-hydroxylase) or the result of intrinsic
changes within the adrenal nodules, similar to those
of testicular adrenal rest tissue in patients with con-
genital adrenal hyperplasia (increased 3b-hydroxysteroid
dehydrogenase activity) (20).
Medical therapy for Cushing’s syndrome due to
BMAH is generally administered for a limited time, before
adrenalectomy and life-long steroid replacement. Clin-
icians may prefer to treat by bilateral adrenalectomy,
considering that patients on medical therapy could stay
mildly hypercortisolic or have fluctuating levels of
cortisol. However, our patient presented constantly
normal urine free cortisol and plasma ACTH during
treatment, never developed a cushingoid appearance and
showed a stable or an improved BMD. This evolution
speaks against a significant chronic hypercortisolism.
Furthermore, safety controls have remained normal
during this long observation. Thus, although not a
common practice, indefinite medical therapy with the
purpose to avoid surgery can be a convenient and safe
approach in some patients with BMAH.
Ketoconazole decreases cortisol secretion in patients
with Cushing’s syndrome in general, on a dose range of
400–1200 mg/day (21). In a large retrospective study in
patients with Cushing’s disease, a median final dose of
600 mg/day ketoconazole was required for the control of
cortisol secretion (22). On the contrary, the BMAH patient
here described, required doses that were in the lowest range
described to control Cushing’s disease. Although in that
retrospective study, the dose did not predict the response,http://www.edmcasereports.comthe small doses required by our patient despite a particu-
larly large adrenal size indicate a relatively inefficient
cortisol secretion by the BMAH nodules, as compared
with adrenal glands that are intrinsically normal but are
submitted to intense ACTH overstimulation.
Our observations also suggest that these low doses
may have prevented adrenal overgrowth. Indeed, the
increase in adrenal size observed at 10 years was minimal
as compared with the massive enlargement of 22.6 and
35.4 ml described under trilostane at 7 years (11), and
probably was within the error of the method of measure-
ment given the complex shape of the glands.
Ketoconazole is metabolised into inactive
compounds, primarily by the liver, and metabolites are
excreted mostly in the faeces, with very little excretion
into the urine. Renal impairment does not seem to cause
accumulation of the drug, but hepatic insufficiency
contraindicates its use (15). Associating other drugs
should be done with caution, because ketoconazole
inhibits microsomal CYP3A4 in the liver and gastrointes-
tinal tract, and may hamper drug metabolism. Most
common side effects at the doses used for fungal infection
(200–400 mg/day) are gastrointestinal, pruritus and liver
dysfunction (15). A meta-analysis reported an incidence
of ketoconazole-induced hepatotoxicity of 3.6–4.2%;
however, in this study hepatotoxicity was defined as an
increase in alanine aminotransferase (ALT) and/or in total
bilirubin (TB) O1! upper normal limit (u.n.l.) on two
consecutive measurements, or an increase in ALT O2!
u.n.l. and/or TB O1! u.n.l. on one measurement (23),
and the actual incidence of severe hepatotoxicity was not
reported. The retrospective study on ketoconazole in
Cushing’s disease reported a mild (!5! u.n.l) and a
major (O5! u.n.l) increase in liver enzymes in 13.5 and
2.5% respectively (22). This drug should nevertheless be
used carefully and liver enzymes measured regularly. In
July 2013, the US Food and Drug Administration and the
European Medicines Agency (EMA) proposed to limit
the use of oral ketoconazole in fungal infections, because
the estimated risks overweighed the benefits, mainly due
to liver toxicity but also due to adrenal insufficiency and
interaction with other drugs (24) (25). However, these
agencies did not give recommendations about its use in
Cushing’s syndrome, and the EMA states that they are
aware that ketoconazole is being used off-label in such
cases. Oral ketoconazole has been used at high doses to
control cortisol secretion in Cushing’s disease, in some
instances for more than 2 years (21), and in non-treatable
ectopic ACTH syndrome.4
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tolerated low dose, can control steroid secretion in BMAH
indefinitely, while preventing adrenal overgrowth. There-
fore, and considering the benign nature of BMAH, this
medical treatment is a convenient alternative to surgery,
for patients who show good response and who can be
appropriately followed up. Regular controls are required
not only for efficacy and drug toxicity but also to detect
subclinical chronic cortisol excess.Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
This research did not receive any specific grant from any funding agency in
the public, commercial or not-for-profit sector.Patient consent
We confirm that written informed consent was obtained from patient for
publication of this case report and associated images.Author contribution statement
S Comte-Perret and F Gomez were directly involved in the management of
this patient. This manuscript has been contributed, seen and approved by
all the authors, who have participated sufficiently in the work to take
public responsibility for its content.References
1 Bourdeau I, D’Amour P, Hamet P, Boutin JM & Lacroix A 2001
Aberrant membrane hormone receptors in incidentally discovered
bilateral macronodular adrenal hyperplasia with subclinical Cushing’s
syndrome. Journal of Clinical Endocrinology and Metabolism 86
5534–5540. (doi:10.1210/jcem.86.11.8062)
2 Vassiliadi DA, Ntali G, Stratigou T, Adali M & Tsagarakis S 2011
Aberrant cortisol responses to physiological stimuli in patients
presenting with bilateral adrenal incidentalomas. Endocrine 40
437–444. (doi:10.1007/s12020-011-9490-1)
3 Louiset E, Duparc C, Young J, Renouf S, Tetsi Nomigni M, Boutelet I,
Libe R, Bram Z, Groussin L, Caron P et al. 2013 Intraadrenal
corticotropin in bilateral macronodular adrenal hyperplasia. New
England Journal of Medicine 369 2115–2125. (doi:10.1056/
NEJMoa1215245)
4 Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau
O, Lefevre L, Sibony M, Guignat L et al. 2013 ARMC5 mutations in
macronodular adrenal hyperplasia with Cushing’s syndrome. New
England Journal of Medicine 369 2105–2114. (doi:10.1056/
NEJMoa1304603)
5 Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ,
Tremblay J, Hamet P, Bourdeau I, Zerbini MC, Pereira MA et al. 2014
ARMC5 mutations are a frequent cause of primary macronodular
adrenal hyperlasia. Journal of Clinical Endocrinology and Metabolism 99
E1501–E1509. (doi:10.1210/jc.2013-4237)http://www.edmcasereports.com6 Lacroix A 2013 Heredity and cortisol regulation in bilateral macro-
nodular adrenal hyperplasia. New England Journal of Medicine 369
2147–2149. (doi:10.1056/NEJMe1312792)
7 Lacroix A 2009 ACTH-independent macronodular adrenal hyperplasia.
Best Practice & Research. Clinical Endocrinology & Metabolism 23 245–259.
(doi:10.1016/j.beem.2008.10.011)
8 Lacroix A, Tremblay J, Rousseau G, Bouvier M & Hamet P 1997
Propranolol therapy for ectopic b-adrenergic receptors in adrenal
Cushing’s syndrome. New England Journal of Medicine 337 1429–1434.
(doi:10.1056/NEJM199711133372004)
9 Preumont V, Mermejo LM, Damoiseaux P, Lacroix A & Maiter D 2011
Transient efficacy of octreotide and pasireotide (SOM230) treatment in
GIP-dependent Cushing’s syndrome. Hormone and Metabolic Research
43 287–291. (doi:10.1055/s-0030-1270523)
10 de Miguel V, Redal MA, Viale ML, Kahan M, Glerean M, Beskow A &
Fainstein Day P 2010 Aberrant expression of glucagon receptors
in adrenal glands of a patient with Cushing’s syndrome and
ACTH-independent macronodular adrenal hyperplasia. Medicina 70
254–256.
11 Obata Y, Yamada Y, Baden MY, Hosokawa Y, Saisho K, Tamba S,
Yamamoto K & Matsuzawa Y 2011 Long-term efficacy of trilostane for
Cushing’s syndrome due to adrenocorticotropin-independent bilateral
macronodular adrenocortical hyperplasia. Internal Medicine 50
2621–2625. (doi:10.2169/internalmedicine.50.5578)
12 Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB,
Wass JA & Besser GM 1991 Short and long-term responses to
metyrapone in the medical management of 91 patients with Cushing’s
syndrome. Clinical Endocrinology 35 169–178. (doi:10.1111/j.1365-
2265.1991.tb03517.x)
13 Omori N, Nomura K, Omori K, Takano K & Obara T 2001 Rational,
effective metyrapone treatment of ACTH-independent bilateral
macronodular adrenocortical hyperplasia (AIMAH). Endocrine Journal
48 665–669. (doi:10.1507/endocrj.48.665)
14 Yoshida M, Umeda H, Iwama S, Nakayama S, Miyata M, Ogawa K,
Maeda H & Oiso Y 2012 Assessment of long-term efficacy and safety
of metyrapone monotherapy in a patient with ACTH-independent
macronodular adrenal hyperplasia. Endocrine 41 160–161.
(doi:10.1007/s12020-011-9549-z)
15 Sonino N 1987 The use of ketoconazole as an inhibitor of steroid
production. New England Journal of Medicine 317 812–818.
(doi:10.1056/NEJM198709243171307)
16 Lacroix A, Mircescu H & Hamet P 1999 Clinical evaluation of the
presence of abnormal hormone receptors in adrenal Cushing’s
syndrome. Endocrinologist 9 15. (doi:10.1097/00019616-
199901000-00004)
17 Yamada Y, Sakaguchi K, Inoue T, Kubo M, Fushimi H, Sekii K, Itatani H,
Tsujimura T & Kameyama M 1997 Preclinical Cushing’s syndrome
due to adrenocorticotropin-independent bilateral adrenocortical
macronodular hyperplasia with concurrent excess of gluco- and
mineralocorticoids. Internal Medicine 36 628–632. (doi:10.2169/inter-
nalmedicine.36.628)
18 Hayashi Y, Takeda Y, Kaneko K, Koyama H, Aiba M, Ikeda U &
Shimada K 1998 A case of Cushing’s syndrome due to ACTH-
independent bilateral macronodular hyperplasia associated with
excessive secretion of mineralocorticoids. Endocrine Journal 45
485–491. (doi:10.1507/endocrj.45.485)
19 Wada S, Kitahama S, Togashi A, Inoue K, Iitaka M & Katayama S 2002
Preclinical Cushing’s syndrome due to ACTH-independent bilateral
macronodular adrenocortical hyperplasia with excessive secretion of
18-hydroxydeoxycorticosterone and corticosterone. Internal Medicine
41 304–308. (doi:10.2169/internalmedicine.41.304)
20 Young J, Couzinet B, Pholsena M, Nahoul K, Labrie F & Schaison G 1994
Plasma 3b-hydroxy-D5-steroids in patients with congenital adrenal
hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical
Endocrinology and Metabolism 78 299–304. (doi:10.1210/jcem.78.2.
8106614)5
S Comte-Perret and others Low-dose ketoconazole
treatment in BMAH
ID: 14-0083; December 2014
DOI: 10.1530/EDM-14-008321 Feelders RA, Hofland LJ & de Herder WW 2010 Medical treatment
of Cushing’s syndrome: adrenal-blocking drugs and ketaconazole.
Neuroendocrinology 92 (Suppl 1) 111–115. (doi:10.1159/000314292)
22 Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D,
Caron P, Luca F, Donadille B, Vantyghem MC et al. 2014
Ketoconazole in Cushing’s disease: is it worth a try? Journal of
Clinical Endocrinology and Metabolism 99 1623–1630. (doi:10.1210/
jc.2013-3628)
23 Yan JY, Nie XL, Tao QM, Zhan SY & Zhang YD 2013 Ketoconazole
associated hepatotoxicity: a systematic review and meta-analysis.http://www.edmcasereports.comBiomedical and Environmental Sciences 26 605–610. (doi:10.3967/0895-
3988.2013.07.13)
24 (FDA) UFaDA. Nizoral (ketoconazole): drug safety communication –
potentially fatal liver injury, risk of drug interactions and adrenal
gland problems. July 26th 2013. www.fda.gov/downloads/Drugs/
DrugSafety/UCM 362444.pd
25 (EMA) EMA. European Medicines Agengy recommends suspension
of marketing authorisations for oral ketoconazole. July 26th 2013.
www.ema.europa.eu/docs/en GB/document library/Press
release/2013/07/WC500146613.pdfReceived in final form 14 October 2014
Accepted 12 November 20146
